A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer

Phase 3

Active, not recruiting

• Conditions: Non-Small Cell Lung Cancer
• Interventions: Drug: Selpercatinib; Drug: Carboplatin; Drug: Cisplatin; Drug: Pemetrexed; Drug: Pembrolizumab

• Registration Number: NCT04194944
• Lead Sponsor: Eli Lilly and Company

Brief Summary

The reason for this study is to see if the study drug selpercatinib compared to a standard treatment is effective and safe in participants with rearranged during transfection (RET) fusion-positive non-squamous non-small cell lung cancer (NSCLC) that has spread to other parts of the body. Participants who are assigned to the standard treatment and discontinue due to progressive disease have the option to potentially crossover to selpercatinib.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2019-12-09
• Study First Submitted QC: 2019-12-09
• Study First Posted: 2019-12-11
• Study Start: 2020-02-17
• Primary Completion: 2023-05-01
• Results First Submitted: 2024-05-03
• Results First Submitted QC: 2024-06-17
• Results First Posted: 2024-06-20
• Status Verified: 2025-04
• Last Update Submitted: 2025-04-17
• Last Update Posted: 2025-04-20
• Study Completion: 2026-06

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 261

Inclusion Criteria

• Histologically or cytologically confirmed, Stage IIIB-IIIC or Stage IV non-squamous NSCLC that is not suitable for radical surgery or radiation therapy.
• A RET gene fusion in tumor and/or blood from a qualified laboratory.
• Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
• Adequate hematologic, hepatic and renal function.
• Willingness of men and women of reproductive potential to observe conventional and highly effective birth control for the duration of treatment and for 6 months after.
• Ability to swallow capsules.

Exclusion Criteria

• Additional validated oncogenic drivers in NSCLC if known.
• Prior systemic therapy for metastatic disease. Treatment (chemotherapy, immunotherapy, or biological therapy) in the adjuvant/neoadjuvant setting is permitted if it was completed at least 6 months prior to randomization.
• Major surgery within 3 weeks prior to planned start of selpercatinib.
• Radiotherapy for palliation within 1 week of the first dose of study treatment or any radiotherapy within 6 months prior to the first dose of study treatment if more than 30 Gy to the lung.
• Symptomatic central nervous system (CNS) metastases, carcinomatous meningitis, or untreated spinal cord compression.
• Clinically significant active cardiovascular disease or history of myocardial infarction within 6 months prior to planned start of selpercatinib or prolongation of the QT interval corrected for heart rate using Fridericia's formula (QTcF) > 470 milliseconds.
• Active uncontrolled systemic bacterial, viral, or fungal infection or serious ongoing intercurrent illness, such as hypertension or diabetes, despite optimal treatment.
• Clinically significant active malabsorption syndrome or other condition likely to affect gastrointestinal absorption of the study drug.
• Pregnancy or lactation.
• Other malignancy unless nonmelanoma skin cancer, carcinoma in situ of the cervix or other in situ cancers or a malignancy diagnosed ≥2 years previously and not currently active.
• Uncontrolled, disease related pericardial effusion or pleural effusion.
• Requiring chronic treatment with steroids.

Exclusion Criteria for Participants Receiving Pembrolizumab:

• History of interstitial lung disease or interstitial pneumonitis.
• Active autoimmune disease or any illness or treatment that could compromise the immune system.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Pemetrexed and Platinum with or without Pembrolizumab - (TRT B)	Pemetrexed	Pemetrexed 500 milligrams per meter squared (mg/m2) administered intravenously (IV) on Day 1, every 3 weeks (Q3W), plus investigator's choice of carboplatin area under the concentration versus time curve 5 (AUC 5 \[maximum dose of 750 mg\] IV), or cisplatin (75 mg/m2 cisplatin IV) on Day 1 Q3W for 4 cycles, plus investigator's choice with or without 200 mg pembrolizumab IV on Day 1 Q3W up to 35 cycles.
Selpercatinib - Treatment A (TRT A)	Selpercatinib	160 milligram (mg) Selpercatinib administered orally twice daily (BID) continuously in 21-day cycles.
Pemetrexed and Platinum with or without Pembrolizumab - (TRT B)	Cisplatin	Pemetrexed 500 milligrams per meter squared (mg/m2) administered intravenously (IV) on Day 1, every 3 weeks (Q3W), plus investigator's choice of carboplatin area under the concentration versus time curve 5 (AUC 5 \[maximum dose of 750 mg\] IV), or cisplatin (75 mg/m2 cisplatin IV) on Day 1 Q3W for 4 cycles, plus investigator's choice with or without 200 mg pembrolizumab IV on Day 1 Q3W up to 35 cycles.
Pemetrexed and Platinum with or without Pembrolizumab - (TRT B)	Carboplatin	Pemetrexed 500 milligrams per meter squared (mg/m2) administered intravenously (IV) on Day 1, every 3 weeks (Q3W), plus investigator's choice of carboplatin area under the concentration versus time curve 5 (AUC 5 \[maximum dose of 750 mg\] IV), or cisplatin (75 mg/m2 cisplatin IV) on Day 1 Q3W for 4 cycles, plus investigator's choice with or without 200 mg pembrolizumab IV on Day 1 Q3W up to 35 cycles.
Pemetrexed and Platinum with or without Pembrolizumab - (TRT B)	Pembrolizumab	Pemetrexed 500 milligrams per meter squared (mg/m2) administered intravenously (IV) on Day 1, every 3 weeks (Q3W), plus investigator's choice of carboplatin area under the concentration versus time curve 5 (AUC 5 \[maximum dose of 750 mg\] IV), or cisplatin (75 mg/m2 cisplatin IV) on Day 1 Q3W for 4 cycles, plus investigator's choice with or without 200 mg pembrolizumab IV on Day 1 Q3W up to 35 cycles.

Primary Outcome Measures

Name	Time	Method
Progression Free Survival (PFS) by Blinded Independent Central Review (BICR) (With Pembrolizumab)	Baseline to Progressive Disease or Death from Any Cause Up to 31 Months	PFS is defined as the time from randomization until the occurrence of documented disease progression by the BICR, per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria, or death from any cause in the absence of BICR-documented progressive disease.
PFS by BICR (With or Without Pembrolizumab)	Baseline to Progressive Disease or Death from Any Cause Up to 31 Months	PFS is defined as the time from randomization until the occurrence of documented disease progression by the BICR, per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria, or death from any cause in the absence of BICR-documented progressive disease.

Secondary Outcome Measures

Name	Time	Method
Percentage of Participant With Disease Control Rate (DCR) by BICR (With Pembrolizumab)	Baseline to Progressive Disease or Death from Any Cause Up to 31 Months	DCR by BICR (with Pembrolizumab) is defined as the number of participants who achieve a BOR of complete response (CR), partial response (PR), or stable disease (SD) lasting 16 or more weeks divided by the total number of participants randomized to each treatment arm.
Overall Response Rate (ORR): Percentage of Participants With Complete Response (CR) or Partial Response (PR) by BICR (With Pembrolizumab)	Baseline through Disease Progression or Death Up to 31 Months	ORR is defined as the number of participants who achieve a best overall response (BOR) of complete response (CR) or partial response (PR) divided by the total number of participants randomized to each treatment arm.
Duration of Response (DoR) by BICR (With Pembrolizumab)	Date of CR or PR to Date of Disease Progression or Death Due to Any Cause Up to 31 Months	DoR was defined as the time from the date that measurement criteria for CR or PR (whichever is first recorded) were first met until the first date that disease was recurrent or documented disease progression was observed, or the date of death from any cause in the absence of documented disease progression or recurrence. The DOR according to both BICR and investigator-assessed BOR was evaluated per RECIST 1.1 criteria.
Percentage of Participant With DCR by BICR (With or Without Pembrolizumab)	Baseline to Progressive Disease or Death from Any Cause Up to 31 Months	DCR by BICR (with or without Pembrolizumab) is defined as the number of participants who achieve a BOR of CR, PR, or SD lasting 16 or more weeks divided by the total number of participants randomized to each treatment arm.
DOR by BICR (With or Without Pembrolizumab)	Date of CR or PR to Date of Disease Progression or Death Due to Any Cause Up to 31 Months	DoR was defined as the time from the date that measurement criteria for CR or PR (whichever is first recorded) were first met until the first date that disease was recurrent or documented disease progression was observed, or the date of death from any cause in the absence of documented disease progression or recurrence. The DOR according to both BICR and investigator-assessed BOR was evaluated per RECIST 1.1 criteria.
OS (With or Without Pembrolizumab)	Baseline to Date of Death from Any Cause Up to 38 Months	Overall survival was defined as the time from randomization until death from any cause. If the participant was alive or lost to follow-up at the time of data analysis, OS data will be censored on the last date the participant is known to be alive.
PFS2 (With Pembrolizumab)	Baseline to Second Disease Progression or Death from Any Cause Up to 38 Months	PFS2 is defined as the time from randomization to disease progression on the next line of treatment or death from any cause in the absence of observed disease progression.
Overall Survival (OS) (With Pembrolizumab)	Baseline to Date of Death from Any Cause Up to 38 Months	Overall survival was defined as the time from randomization until death from any cause. If the participant was alive or lost to follow-up at the time of data analysis, OS data was censored on the last date the participant is known to be alive.
Median Intracranial DOR Per RECIST 1.1 by BICR (With or Without Pembrolizumab)	Date of Intracranial CR or PR to Date of CNS Progression or Death Due to Any Cause Up to 31 Months	Median Intracranial DOR per RECIST 1.1 by BICR (with or without Pembrolizumab)
Time to Deterioration of Pulmonary Symptoms (With Pembrolizumab)	Baseline to Deterioration of Pulmonary Symptoms Up to 31 Months	Time to Deterioration of Pulmonary Symptoms Measured by the NSCLC-Symptom Assessment Questionnaire (SAQ) (with Pembrolizumab)
Intracranial ORR: Percentage of Participants With Intracranial CR or PR Per Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) by BICR (With Pembrolizumab)	Baseline through CNS Progression or Death Up to 31 Months	Intracranial ORR: Percentage of Participants with Intracranial CR or PR per RANO-BM by BICR (with Pembrolizumab)
Median Intracranial DOR Per RECIST 1.1 by BICR (With Pembrolizumab)	Date of Intracranial CR or PR to Date of CNS Progression or Death Due to Any Cause Up to 31 Months	Intracranial DOR per RECIST 1.1 by BICR (with Pembrolizumab)
Intracranial ORR: Percentage of Participants With Intracranial CR or PR Per RECIST 1.1 by BICR (With or Without Pembrolizumab)	Baseline through CNS Progression or Death Up to 31 Months	Intracranial ORR: Percentage of Participants with Intracranial CR or PR per RECIST 1.1 by BICR (with or without Pembrolizumab)
The Concordance of the Local Lab and the Central Lab RET Results: Percentage of Participants With RET-Positive Specimens as Called by the Central Lab, Which is Also RET-Positive as Called by a Local Lab (Positive Percent Agreement)	Baseline	The Concordance of the Local Lab and the Central Lab RET Results: Percentage of Participants with RET-Positive Specimens as Called by the Central Lab, which is also RET-Positive as Called by a Local Lab (Positive Percent Agreement)
Median Time to CNS Progression Per RECIST 1.1 by BICR (With or Without Pembrolizumab)	Baseline through CNS Progression or Death Up to 31 Months	Time to CNS Progression per RECIST 1.1 by BICR (with or without Pembrolizumab)
Intracranial DOR Per RANO-BM by BICR (With Pembrolizumab)	Date of Intracranial CR or PR to Date of CNS Progression or Death Due to Any Cause Up to 31 Months	Intracranial DOR per RANO-BM by BICR (with Pembrolizumab)
PFS2 (With or Without Pembrolizumab)	Baseline to Second Disease Progression or Death from Any Cause Up to 38 Months	PFS2 is defined as the time from randomization to disease progression on the next line of treatment or death from any cause in the absence of observed disease progression.
ORR: Percentage of Participants With CR or PR by BICR (With or Without Pembrolizumab)	Baseline through Disease Progression or Death Up to 31 Months	ORR is defined as the number of participants who achieve a best overall response (BOR) of complete response (CR) or partial response (PR) divided by the total number of participants randomized to each treatment arm.
Time to Deterioration of Pulmonary Symptoms (With or Without Pembrolizumab)	Baseline to Deterioration of Pulmonary Symptoms Up to 31 Months	Time to Deterioration of Pulmonary Symptoms Measured by the NSCLC-SAQ (with or without Pembrolizumab)
Median Time to CNS Progression Per RECIST 1.1 by BICR (With Pembrolizumab)	Baseline through CNS Progression or Death Up to 31 Months	Time to CNS Progression per RECIST 1.1 by BICR (with Pembrolizumab)
Intracranial DOR Per RANO-BM by BICR (With or Without Pembrolizumab)	Date of Intracranial CR or PR to Date of CNS Progression or Death Due to Any Cause Up to 31 Months	Intracranial DOR per RANO-BM by BICR (with or without Pembrolizumab)
Intracranial ORR: Percentage of Participants With Intracranial CR or PR Per RANO-BM by BICR (With or Without Pembrolizumab)	Baseline through CNS Progression or Death Up to 31 Months	Intracranial ORR: Percentage of Participants with Intracranial CR or PR per RANO-BM by BICR (with or without Pembrolizumab)
Intracranial ORR: Percentage of Participants With Intracranial CR or PR Per RECIST (Response Evaluation Criteria in Solid Tumors) 1.1 by BICR (With Pembrolizumab)	Baseline through Central Nervous System (CNS) Progression or Death up to 31 Months	Intracranial ORR: Percentage of Participants with Intracranial CR or PR per RECIST 1.1 by BICR (with Pembrolizumab)

Trial Locations

Locations (194)

Jeroen Bosch Hospital; 🇳🇱 Den Bosch, Noord-Brabant, Netherlands

Abdurrahman Yurtaslan Ankara Oncology, education and Research Hospital; 🇹🇷 Ankara, Turkey

Centro de Oncología e Investigación de Buenos Aires; 🇦🇷 Berazategui, Buenos Aires, Argentina

Fundacion CENIT para la Investigacion en Neurociencias; 🇦🇷 Caba, Buenos Aires, Argentina

Clinica Viedma; 🇦🇷 Viedma, Río Negro, Argentina

Alexander Fleming; 🇦🇷 Ciudad de Buenos Aires, Argentina

Clínica El Castaño; 🇦🇷 San Juan, Argentina

Chris O'Brien Lifehouse; 🇦🇺 Camperdown, New South Wales, Australia

Calvary Mater Newcastle; 🇦🇺 Waratah, New South Wales, Australia

Westmead Hospital; 🇦🇺 Westmead, New South Wales, Australia

Scroll for more (184 remaining)